New paper by Dr. Jean-Philippe Theurillat Lab

news on 21 Sep , 2017

The publication in the renowned scientific journal Nature Medicine describes how the degradation of BET proteins are regulated by point mutations in the ubiquitin ligase adaptor protein SPOP and how this affects the sensitivity to BET protein inhibitors – a class of chromatin interacting small molecules that are currently in clinical development.


Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Accepted for publication /Nat Med/ 2017